You have to look at the model they had also. And

You have to look at the model they had also. And leonlimab has certain advantages to current treatment.

Quote:

---

Achaogen ... like other recently closed antibiotics companies, could not make a sufficient return on its investment because antibiotics are used infrequently and for short durations while new antibiotics are held in reserve to protect their effectiveness. The closing of Achaogen further decreases the likelihood that investors will risk supporting antibiotic research and development, in spite of the immediate and pressing need for these drugs.”

---

Quote:

---

it is possible that the only approval leronlimab will ever get is for combo

---

Yeah, but combo with general HIV population. It will get more than a mdr2+ approval. When phase 3 mono pivotal is approved, around the time of BLA submission if all goes according to plan, leronlimab should get some attention. Because there is a great change it can do the work by itself, the low bar becomes probably a 2 drug combo, weekly dosing, (which would be killer —or 3, but very likely 2) in my opinion. Go back and listen to Dr. Lalezari in the CC. They have potential partners, last year I believe one offered to even fund the trials (CC last November), but CytoDyn first will go the mono path, with that being a backup.